Anvisa follows technical analysis; Government bets on registration until the end of 2025 to start national immunization.
The vaccine against dengue Developed by the Butantan Institute is still under analysis by the National Health Surveillance Agency (Anvisa), but approval may occur soon.
The expectation of the federal government is that, with the completion of the regulatory process, the dose is available for use in a national immunization program in early 2026, as informs the Brazil agency.
“The process is under evaluation. Anvisa has been asked technical questions, and Butantan has been answering all the necessary data,” explained Health Minister Alexandre Padilha, on Tuesday (25), during an interview with radios in the program in the program Good morning, ministerof the Brazil Communication Company (EBC).
- Dengue is an infectious disease transmitted by the mosquito Aedes aegypti.
- In 2025, according to Padilha, there was more than 70% drop in cases and 80% in deaths compared to 2024.
- However, the state of São Paulo concentrated most occurrences and deaths in 2025.
Read more:
Precautions for the second semester
The minister pointed out that the months of June and July mark the end of the period of largest transmission. From August, the focus will be to intensify preventive and informative actions in the municipalities, preparing the country for the new transmission cycle that begins in January.
“We will work very strongly in August and September, already in the second half, for municipalities and state governments to begin prevention, control and information actions to the population,” said the minister.
“We want by the end of 2025 the vaccine to be registered, based on the partnership between Anvisa and Butantan. We are working hard for it,” concluded Padilha.
Collaboration for the digital look
Leandro Criscuolo is a journalist graduated from Cásper Líbero College. He has worked as Copywriter, digital marketing analyst and social networking manager. Currently, he writes for the digital look.
